You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

TGA business plan 2014-2015

Therapeutic Goods Administration

25 November 2014

Book pagination

Funding, capital expenditure and anticipated revenue

Our finances are managed through the Therapeutic Goods Special Account (under Section 80 of the Public Governance, Performance and Accountability Act 2013 and Section 45 of the Therapeutic Goods Act 1989).

TGA's activities are fully cost recovered from fees and charges imposed on industry, with the exception of Government funding provided for the alignment of Australia and New Zealand therapeutic arrangements, and departmental funding for the operation of the Drug Control Section and Medicines Scheduling Secretariat.

Portfolio budget statements

Budgeted expenses
Actual expenditure
Estimated expenditure

TGA Special Account



Budgeted increase in expenditure (including capital) comprises:
Estimated actual 2013-14 $137,334,000
Capital expenditure $5,587,000
Supplier expenses ($782,000)
Employee expenses ($121,000)
Government programs $5,718,000
Budgeted expenses 2014-15 (including capital) $147,736,000

The increase in expenditure (including capital) in 2014-15 relates to funding provided for Government budget measures and capital funding for the Business Improvement Program.

Approved capital expenditure
Out year 1
Out year 2
Out year 3
Approved internally funded projects $15,231,000 $10,621,000 $7,710,000 $5,710,000

Capital expenditure includes funding for the Business Improvement Program, funding for Government budget measures and standard lifecycle replacement programs for property, information technology and laboratory equipment.

Anticipated revenue movements
2014-15 2015-16 2016-17
Anticipated revenue $138,658,000 $135,260,000 $136,593,000

Book pagination